Aliso Viejo-based Glaukos Corp. shares rose 17% in after-hours trading after reporting better-than-expected third-quarter results.
Revenue increased 58% to $211 million, coming in above the $168.8 million analyst estimate.
“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa,” Chairman and Chief Executive Thomas Burns said in a statement.
The ophthalmic company also raised 2026 net sales guidance to $775 million to $785 million, up from its previous range of $680 million to $700 million.
Glaukos (NYSE: GKOS) jumped 17% to $213 apiece after the market closed. They ended regular trading at $181.43 per share and a $10.7 billion market cap.
